Medicare opens door wide for Gilead's $84K hep C drug Sovaldi

Save

The most effective weapon to date against hepatitis C, Gilead's new drug Sovaldi, has raised the ire of drug-cost watchdogs worldwide with its $84,000 price tag. That's not stopping the largest U.S. government payer from giving the product a major push. The Centers for Medicare & Medicaid Services says in a memo that it will start covering hep C screening for adults at high risk for the virus or for any of its beneficiaries who were born between 1945 and 1965.